{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:58Z","timestamp":1781632498537,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J NeuroEngineering Rehabil"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain-computer interfaces (BCIs) have emerged as powerful tools to restore neurological function lost due to injury or degeneration. Despite scientific advancements, successful commercialization remains challenging. This article analyzes two rehabilitative BCIs\u2014the Argus II retinal prosthesis by Second Sight and the ARC-IM spinal cord stimulation system by Onward Medical\u2014as case studies to highlight critical factors influencing their commercialization outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main text<\/jats:title>\n                    <jats:p>The Argus II, initially heralded as groundbreaking, restored partial vision to patients blinded by retinitis pigmentosa through direct retinal stimulation. Despite clinical success and initial regulatory approvals leveraging reduced barriers via humanitarian device exemptions, it struggled commercially due to an insufficient patient population, prohibitive manufacturing costs, and high procedural and postoperative rehabilitation costs. Physician adoption barriers, driven by the unfamiliar surgical procedure and reimbursement challenges, further limited its scalability, ultimately leading to market withdrawal. Conversely, Onward Medical adopted a phased commercialization approach with its ARC systems targeting spinal cord injuries. Initially releasing the non-invasive ARC-EX device, Onward built clinical traction and provider relationships, strategically fostering familiarity to minimize early risk and regulatory burden. Leveraging established spinal cord stimulation technology widely familiar to physicians, Onward positioned its invasive ARC-IM system more favorably for broader adoption. Despite remaining challenges, such as surgical complexity, postoperative rehabilitation infrastructure, and cost, this methodical strategy may significantly mitigate commercial and clinical barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Comparative analysis of Argus II and ARC-IM underscores that thoughtful commercialization strategies emphasizing phased product introduction, leveraging predicate technologies, and aligning closely with established clinical practices are essential to translating BCI technologies from scientific milestones into sustainable clinical solutions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12984-025-01811-9","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:05:07Z","timestamp":1769677507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain-computer interface commercialization"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4302-1306","authenticated-orcid":false,"given":"Jackson","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-6083","authenticated-orcid":false,"given":"Anson","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"1811_CR1","unstructured":"Brain computer interface is growing but what are the risks?. World Economic Forum. 2024. https:\/\/www.weforum.org\/stories\/2024\/06\/the-brain-computer-interface-market-is-growing-but-what-are-the-risks\/."},{"key":"1811_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exer.2007.03.001","volume":"85","author":"EL Berson","year":"2007","unstructured":"Berson EL. Long-Term visual prognoses in patients with retinitis Pigmentosa. The Ludwig von Sallmann lecture. Exp Eye Res. 2007;85:7\u201314.","journal-title":"Exp Eye Res"},{"key":"1811_CR3","unstructured":"Belluck P. Device offers partial vision for the blind. New York Times. 2013."},{"key":"1811_CR4","unstructured":"Their Bionic Eyes Are Now Obsolete and Unsupported. IEEE Spectr. https:\/\/spectrum.ieee.org\/bionic-eye-obsolete"},{"key":"1811_CR5","unstructured":"Second Sight Medical Products Inc. FDA Panel Recommends FDA Approval for Second Sight\u2019s Argus\u00ae II Retinal Prosthesis System. 2012. https:\/\/www.asrs.org\/content\/documents\/fda_panel_results_release_-_final.pdf."},{"key":"1811_CR6","unstructured":"Health CforD, Humanitarian Device R. Exemption. FDA. 2025. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/humanitarian-device-exemption."},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1586\/17434440.2014.862494","volume":"11","author":"HC Stronks","year":"2014","unstructured":"Stronks HC, Dagnelie G. The functional performance of the Argus II retinal prosthesis. Expert Rev Med Devices. 2014;11:23\u201330.","journal-title":"Expert Rev Med Devices"},{"key":"1811_CR8","unstructured":"Road FFB. P.-5555 6925 O. M. Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs. Foundation Fighting Blindness https:\/\/www.fightingblindness.org\/news\/second-sight-agrees-to-merger-to-maintain-retinal-and-cortical-prostheses-programs-830"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/OPTH.S137525","volume":"12","author":"AP Finn","year":"2018","unstructured":"Finn AP, Grewal DS, Vajzovic L. Argus II retinal prosthesis system: a review of patient selection criteria, surgical considerations, and post-operative outcomes. Clin Ophthalmol. 2018;12:1089\u201397.","journal-title":"Clin Ophthalmol"},{"key":"1811_CR10","unstructured":"Collins J, Second Sight Just Quintupled Its Addressable Market. Forbes https:\/\/www.forbes.com\/sites\/greatspeculations\/2015\/07\/22\/second-sight-just-quintupled-its-addressable-market\/"},{"key":"1811_CR11","unstructured":"Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results. Vivani Medical, Inc. 2020.https:\/\/investors.vivani.com\/investors\/news-events\/press-releases\/detail\/26\/second-sight-reports-fourth-quarter-and-full-year-2019."},{"key":"1811_CR12","unstructured":"Densford F. Second Sight wins CMS reimbursement codes for Argus II \u2018bionic eye\u2019. MassDevice. 2016. https:\/\/www.massdevice.com\/second-sight-wins-cms-reimbursement-codes-argus-ii-bionic-eye\/."},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2415-14-49","volume":"14","author":"A Vaidya","year":"2014","unstructured":"Vaidya A, et al. The cost-effectiveness of the Argus II retinal prosthesis in retinitis pigmentosa patients. BMC Ophthalmol. 2014;14:49.","journal-title":"BMC Ophthalmol"},{"key":"1811_CR14","unstructured":"United States Securities and Exchange Commission. Second Sight Medical Products Inc Form 10-K. 2014."},{"key":"1811_CR15","unstructured":"Second Sight Medical Products, Inc. Argus\u00ae II Retinal Prosthesis System Surgeon Manual. 2013. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf11\/h110002c.pdf"},{"key":"1811_CR16","unstructured":"Collins J, Why Argus II, Reimbursement Wins Keep Me Bullish On Second Sight. Forbes https:\/\/www.forbes.com\/sites\/greatspeculations\/2015\/06\/05\/why-reimbursement-wins-for-argus-ii-keep-me-bullish-on-second-sight\/"},{"key":"1811_CR17","unstructured":"National Institute for Health and Care Excellence. Interventional procedure overview of insertion of an epiretinal prosthesis for retinitis pigmentosa. Interventional Procedures Programme. 2014. https:\/\/www.nice.org.uk\/guidance\/ipg519\/evidence\/insertion-of-an-epiretinal-prosthesis-for-retinitis-pigmentosa-overview2"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12886-020-01475-0","volume":"20","author":"E Lee","year":"2020","unstructured":"Lee E, Balasingam B, Mills EC, Zarei-Ghanavati M, Liu C. A survey exploring ophthalmologists\u2019 attitudes and beliefs in performing immediately sequential bilateral cataract surgery in the united Kingdom. BMC Ophthalmol. 2020;20:210.","journal-title":"BMC Ophthalmol"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/papr.12692","volume":"18","author":"A Sdrulla","year":"2018","unstructured":"Sdrulla A, Guan Y, Raja S. Spinal cord stimulation: clinical efficacy and potential mechanisms. Pain Pract. 2018;18:1048\u201367.","journal-title":"Pain Pract"},{"key":"1811_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.2","volume":"3","author":"L Colloca","year":"2017","unstructured":"Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:1\u201319.","journal-title":"Nat Rev Dis Primers"},{"key":"1811_CR21","unstructured":"Spinal cord injury. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/spinal-cord-injury"},{"key":"1811_CR22","unstructured":"NV OM. ONWARD Announces First-in-Human Use of ARC-IM\u2122 Lead to Restore Movement and Function after Spinal Cord Injury. GlobeNewswire News Room. 2023. https:\/\/www.globenewswire.com\/news-release\/2023\/05\/15\/2669087\/0\/en\/ONWARD-Announces-First-in-Human-Use-of-ARC-IM-Lead-to-Restore-Movement-and-Function-after-Spinal-Cord-Injury.html."},{"key":"1811_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41591-024-02940-9","volume":"30","author":"C Moritz","year":"2024","unstructured":"Moritz C, et al. Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial. Nat Med. 2024;30:1276\u201383.","journal-title":"Nat Med"},{"key":"1811_CR24","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2004.21.1371","author":"KD Anderson","year":"2004","unstructured":"Anderson KD Targeting recovery: priorities of the spinal Cord-Injured population. J Neurotrauma. 2004. https:\/\/doi.org\/10.1089\/neu.2004.21.1371.","journal-title":"https:\/\/home Liebertpub com\/neu"},{"key":"1811_CR25","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1089\/neu.2011.2226","volume":"29","author":"LA Simpson","year":"2012","unstructured":"Simpson LA, Eng JJ, Hsieh JTC. Wolfe and the spinal cord injury rehabilitation evidence (SCIRE) research Team, D. L. The health and life priorities of individuals with spinal cord injury: A systematic review. J Neurotrauma. 2012;29:1548\u201355.","journal-title":"J Neurotrauma"},{"key":"1811_CR26","unstructured":"Courtine G, Bloch J, Squair J, Phillips A, Mahe L. T. R. System for micturition control in a mammal with bladder disfunction. 2024."},{"key":"1811_CR27","unstructured":"Courtine G, Phillips A, Squair J. System and method for control of autonomic function. 2022."},{"key":"1811_CR28","unstructured":"Courtine G, Phillips A, Squair J, Darrow D. System and method for closed loop control of autonomic function. 2022."},{"key":"1811_CR29","unstructured":"Bloch J et al. Neuromodulation\/neurostimulation system for controlling a respiratory function. 2024."},{"key":"1811_CR30","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41591-023-02584-1","volume":"29","author":"T Milekovic","year":"2023","unstructured":"Milekovic T, et al. A spinal cord neuroprosthesis for locomotor deficits due to Parkinson\u2019s disease. Nat Med. 2023;29:2854\u201365.","journal-title":"Nat Med"},{"key":"1811_CR31","volume-title":"Spinal cord stimulator Implant. In StatPearls","author":"AM Dydyk","year":"2025","unstructured":"Dydyk AM, Tadi P. Spinal cord stimulator Implant. In StatPearls. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"1811_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/jamaneurol.2019.3523","volume":"76","author":"S Hendriks","year":"2019","unstructured":"Hendriks S, et al. Ethical challenges of Risk, informed Consent, and posttrial responsibilities in human research with neural devices: A review. JAMA Neurol. 2019;76:1506\u201314.","journal-title":"JAMA Neurol"},{"key":"1811_CR33","unstructured":"Orion. Cortigent | Powering brain connections to restore body functions. https:\/\/www.cortigent.com\/orion"},{"key":"1811_CR34","unstructured":"Second Sight Medical Products. Early Feasibility Study of the Orion Visual Cortical Prosthesis System. 2025. https:\/\/clinicaltrials.gov\/study\/NCT03344848."}],"container-title":["Journal of NeuroEngineering and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12984-025-01811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12984-025-01811-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12984-025-01811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:18:43Z","timestamp":1781630323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12984-025-01811-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1186\/s12984-025-01811-9","relation":{},"ISSN":["1743-0003"],"issn-type":[{"value":"1743-0003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants, human data, or human tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}